News About: Pharm. Industry
Does planning out for the next year’s business strategy mean anything to pharmaceutical companies in this cloudy environment?
‘Does it really mean anything?’
As the end of the year has come closer, pharmaceutical companies have got into planning out business strategies for the next year, but have suffered guiding its directions.
Since freq...
Noticeable directions of Green Cross towards anticancer drug developmentIt is observed that Green Cross is moving in the right direction to develop anticancer drugs.
Green Cross announced on the 3rd that the Ministry of Food and Drug Safety approve...
|
‘Viread’ with KRW 65 billion and ‘Trajenta’ with KRW 58.3 billion… their unstoppable races
The Yuhan Corporation’s unstoppable race with its pharmaceutical products has caught everyone’s attention.
Its products have been in the center of attraction in the pharmaceutical market as the company recorded the t...
The most quarterly R&D investment of Hanmi Pharmaceutical since it foundationHanmi Pharmaceutical is advancing on development of new global drugs as it continues the biggest quarterly investment since its foundation.
Hanmi Pharmaceutical made a public a...
|
Pharmaceutical companies’ internal controls over illegal dealership will bring difficulties for medical representatives
Ever since each pharmaceutical company has tightened internal business controls after enforcement of the ‘Rebate Two Out System’, the position of medical representatives (MRs) are getting weaker.
Especially, due to r...
Pharmaceutical companies are trying to follow the fair racing compliance program with their ‘all strength’
It was observed that pharmaceutical companies have tried the best to satisfy the government’s effort to eradicate the drug rebate system.
Followed by the enforcement of the ‘Rebate Double Punishment’ to penalize both...
The tentative performance result of 10 pharmaceutical companies on the third quarter of the year
It was observed that the major listed pharmaceutical companies in Korea showed poor sales performance on the third quarter of the year.
According to the third quarter tentative performance result of the 10 pharmaceut...
Pfizer Korea stated “We need some time to review the distribution cost raise”
It was told that Pfizer Korea, which is confronting a faceoff against the pharmaceutical distribution industry over distribution cost, announced its positive opinion for the distribution cost raise.
According to the ...
Daewoong Pharmaceutical issued company stocks worth of KRW 100 billion
Daewoong Pharmaceutical announced on the 30th that the company completed issuing non-guaranteed bonds worth of KRW 100 billion to construct a factory in Osong, Chungcheongbuk-do, Korea.
The newly issued company stock...
An increasing curve of new hypertriglyceridemia drugs
New hypertriglyceridemia drugs are drawing attention in the pharmaceutical market.
Hypertriglyceridemia is one of the dyslipidemias, which is more common than hypercholesteremia and which must requires appropriate me...
